Covid vaccine booster raises antibody levels in fight against OmicronA third dose of vaccine has been shown to effectively neutralise the Omicron variant of covid-19, according to Share XCovid vaccine booster raises antibody levels in fight against Omicronhttps://pharmaphorum.com/news/covid-vaccine-booster-raises-antibody-levels-in-fight-against-omicron/
Japan approves Pfizer COVID vaccine for children aged 5 to 11Japan’s health ministry has authorised the use of Pfizer and BioNTech COVID-19 vaccine in children aged between five Share XJapan approves Pfizer COVID vaccine for children aged 5 to 11https://pharmaphorum.com/news/japan-approves-pfizer-covid-vaccine-for-children-aged-5-to-11/
Nine for 2022: innovation and opportunities in healthcareIn the second part of our examination of issues that will shape the course of 2022, we’ll update Share XNine for 2022: innovation and opportunities in healthcarehttps://pharmaphorum.com/digital/2022-innovation-opportunities-healthcare-digital/
Look out GSK, Pfizer and BioNTech are coming for ShingrixGlaxoSmithKline places shingles vaccine Shingrix is among its top prospects, with peak sales potential of almost $6 billion. Share XLook out GSK, Pfizer and BioNTech are coming for Shingrixhttps://pharmaphorum.com/news/look-out-gsk-pfizer-and-biontech-are-coming-for-shingrix/
Nine for 2022: International issues that are compelling, new or changed in 2022The year 2020 ended on a note of hope, with the 8th December vaccination of 91-year-old Margaret Keenan, Share XNine for 2022: International issues that are compelling, new or changed in 2022https://pharmaphorum.com/r-d/international-issues-compelling-new-changed-2022/
Sanofi snaps up acne vaccine developer Origimm BioSanofi has added to its vaccine pipeline with an agreement to acquire Austria’s Origimm Biotechnology and its vaccine-based Share XSanofi snaps up acne vaccine developer Origimm Biohttps://pharmaphorum.com/news/sanofi-snaps-up-acne-vaccine-developer-origimm-bio/
Report suggests UK’s national vaccine facility is on the blockThe UK’s Vaccines Manufacturing and Innovation Centre (VMIC) – unveiled with fanfare by the government in 2018 – Share XReport suggests UK’s national vaccine facility is on the blockhttps://pharmaphorum.com/news/report-suggests-uks-national-vaccine-facility-is-on-the-block/
Trial of intranasal Alzheimer’s vaccine gets underway in USThe first patients are now being treated as part of a first-in-human trial of a vaccine, administered as Share XTrial of intranasal Alzheimer’s vaccine gets underway in UShttps://pharmaphorum.com/news/trial-of-intranasal-alzheimers-vaccine-gets-underway-in-us/
Vaccibody rebrands as Nykode, and unveils big Regeneron partnershipNorwegian biotech Vaccibody has changed its name to Nykode Therapeutics, and celebrated its new identity with a sizeable Share XVaccibody rebrands as Nykode, and unveils big Regeneron partnershiphttps://pharmaphorum.com/news/vaccibody-rebrands-as-nykode-and-unveils-big-regeneron-partnership/
